Partner Content Partner Content 10 Key Reasons to attend SMi’s 10th Annual Biosimilars Confe... 10 Key Reasons to attend Biosimilars
Partner Content Partner Content Michel Mikhail invites Biosimilar experts to attend SMi’s 10... Michel Mikhail invites Biosimilar experts to attend SMi
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
